Nektar Therapeutics Sells U.S. Royalty Rights for $400M
Ticker: NKTR · Form: 8-K · Filed: Jun 27, 2025 · CIK: 906709
Sentiment: neutral
Topics: divestiture, royalty sale, financing
Related Tickers: NKTR
TL;DR
Nektar selling US Rezdiffra royalties to Baker Brothers for $400M upfront. Closing Q3.
AI Summary
Nektar Therapeutics announced on June 27, 2025, that it has entered into a definitive agreement to sell its U.S. royalty rights for the drug Rezdiffra to an affiliate of Baker Brothers Investments for an upfront payment of $400 million. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions.
Why It Matters
This significant divestiture provides Nektar with substantial capital, potentially impacting its future research and development strategies and financial flexibility.
Risk Assessment
Risk Level: medium — The sale of royalty rights introduces financial risk related to future drug performance and the company's strategic direction post-transaction.
Key Numbers
- $400 million — Upfront Payment (Received by Nektar Therapeutics for U.S. royalty rights of Rezdiffra.)
Key Players & Entities
- Nektar Therapeutics (company) — Seller of royalty rights
- Rezdiffra (drug) — Drug whose U.S. royalty rights are being sold
- Baker Brothers Investments (company) — Buyer of royalty rights
- $400 million (dollar_amount) — Upfront payment for royalty rights
- June 27, 2025 (date) — Date of announcement
- third quarter of 2025 (date) — Expected closing period
FAQ
What specific U.S. royalty rights is Nektar Therapeutics selling?
Nektar Therapeutics is selling its U.S. royalty rights for the drug Rezdiffra.
Who is the buyer of these royalty rights?
The buyer is an affiliate of Baker Brothers Investments.
What is the total upfront payment for the transaction?
The upfront payment is $400 million.
When is the transaction expected to close?
The transaction is expected to close in the third quarter of 2025.
What conditions must be met for the sale to close?
The sale is subject to customary closing conditions.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 27, 2025 regarding NEKTAR THERAPEUTICS (NKTR).